0001209191-18-057429.txt : 20181106
0001209191-18-057429.hdr.sgml : 20181106
20181106170047
ACCESSION NUMBER: 0001209191-18-057429
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181102
FILED AS OF DATE: 20181106
DATE AS OF CHANGE: 20181106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CRANDELL KEITH
CENTRAL INDEX KEY: 0001219039
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38720
FILM NUMBER: 181163812
MAIL ADDRESS:
STREET 1: 8755 W. HIGGINS ROAD
STREET 2: SUITE 1025
CITY: CHICAGO
STATE: IL
ZIP: 60631
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Twist Bioscience Corp
CENTRAL INDEX KEY: 0001581280
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 462058888
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 455 MISSION BAY BOULEVARD SOUTH, SUITE 5
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 800-719-0671
MAIL ADDRESS:
STREET 1: 455 MISSION BAY BOULEVARD SOUTH, SUITE 5
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-11-02
0
0001581280
Twist Bioscience Corp
TWST
0001219039
CRANDELL KEITH
8755 W. HIGGINS ROAD, SUITE 1025
CHICAGO
IL
60631
1
0
1
0
Common Stock
2018-11-02
4
C
0
1182645
A
1182645
I
See footnotes
Common Stock
2018-11-02
4
C
0
718275
A
1900920
I
See footnotes
Common Stock
2018-11-02
4
C
0
266776
A
2167696
I
See footnotes
Common Stock
2018-11-02
4
C
0
224726
A
2392422
I
See footnotes
Common Stock
2018-11-02
4
P
0
15000
14.00
A
2407422
I
See footnotes
Common Stock
2018-11-02
4
C
0
894146
A
894146
I
See footnotes
Common Stock
2018-11-02
4
P
0
60000
14.00
A
954146
I
See footnotes
Common Stock
0
D
Series A Preferred Stock
2018-11-02
4
C
0
1182645
D
Common Stock
1182645
0
I
See footnotes
Series B Preferred Stock
2018-11-02
4
C
0
718275
D
Common Stock
718275
0
I
See footnotes
Series C Preferred Stock
2018-11-02
4
C
0
266776
D
Common Stock
266776
0
I
See footnotes
Series D Preferred Stock
2018-11-02
4
C
0
224726
D
Common Stock
224726
0
I
See footnotes
Series D Preferred Stock
2018-11-02
4
C
0
894146
D
Common Stock
894146
0
I
See footnotes
Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis.
The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Keith Crandell is a managing director of ARCH VII LLC and AVP GPLLC, and may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Mr. Crandell disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Reflects shares purchased in the Issuer's initial public offering.
The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
The expiration date is not relevant to the conversion of these securities.
/s/ William Solis, as Attorney-in-Fact
2018-11-06